1518 Ratified PICO Confirmation
Application 1518:Endoscopic visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasiaPICO Confirmation(To guide a new application to MSAC)(Version 1.0)Summary of PICO criteria to define the question(s) to be addressed in an Assessment Report to the Medical Services Advisory Committee (MSAC)This PICO confirmation is for a treatment already listed on the MBS. The Applicants are seeking an increased fee, to be consistent with the main comparator, with the claim of non-inferiority between the intervention and comparator. Table SEQ Table \* ARABIC 1PICO components to assess VLAP for men with BPH ComponentDescriptionPatientsMen with severe or high impact symptoms (LUTS) of benign prostatic hyperplasia (BPH) InterventionVisual laser ablation of the prostate (VLAP) using a non-contact (side firing) endoscopic approachComparatorTransurethral resection of the prostate (TURP)OutcomesSafetya:Immediate surgical complications – bleeding, acute urinary retention, infection, TURP syndrome (dilutional hyponatraemia), mortalityLonger term complications – urethral stricture, erectile dysfunction, urinary incontinenceClinical effectivenessa:Symptoms of BPH and LUTS, including International Prostate Symptom Score (IPSS)Peak flow (Qmax)Post-void residual volumeProstate volumeQuality of lifeTreatment failure rate, re-intervention rateDetection rate of prostate cancer by histology following TURP and clinical impact of thisHealthcare resources: length of hospital stay in Australiab, cost of consumables, co-claiming data for VLAP and TURP, out-of-pocket costs to consumersTotal Australian Government healthcare costs: financial impact of proposed fee increaseBPH = benign prostatic hyperplasia; HoLEP = holmium laser enucleation of the prostate; IPSS = international prostate symptom score; LUTS = lower urinary tract symptoms; TURP = transurethral resection of the prostate; VLAP = visual laser ablation of the prostatea Evidence for safety and effectiveness may be based on the GOLIATH randomised controlled trial. Other studies comparing laser and TURP should also be included to support GOLIATH data. b Consider datasets such as private health insurance.PICO rationale for therapeutic medical services PopulationBenign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, in which smooth muscle and epithelial cells proliferate. It is a complex progressive disease occurring in a large proportion of older men. Although it is not cancerous, BPH can progress to cause lower urinary tract symptoms (LUTS) that can impact on a man’s quality of life, and physical health ADDIN EN.CITE <EndNote><Cite><Author>Pascoe</Author><Year>2017</Year><RecNum>10</RecNum><IDText>S133-41</IDText><DisplayText>(Pascoe et al. 2017)</DisplayText><record><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515634404">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pascoe, C.</author><author>Ow, D.</author><author>Perera, M.</author><author>Woo, H. H.</author><author>Jack, G.</author><author>Lawrentschuk, N.</author></authors></contributors><auth-address>University of Melbourne, Department of Surgery, Austin Hospital, Melbourne, Australia;
Young Urology Researchers Organisation (YURO), Melbourne, Australia;
Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, Australia;
Olivia Newton-John Cancer Research Institute, Melbourne, Australia;
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia</auth-address><titles><title>Optimising patient outcomes with photoselective vaporization of the prostate (PVP): a review</title><secondary-title>Transl Androl Urol</secondary-title></titles><periodical><full-title>Transl Androl Urol</full-title></periodical><pages>S133-41</pages><volume>6</volume><number>Suppl 2</number><dates><year>2017</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>2223-4691 (Electronic)</isbn><accession-num>28791232</accession-num><urls></urls></record></Cite></EndNote>(Pascoe et al. 2017). LUTS include an increased frequency or urgency of urination, increased urination at night, difficulty stopping or starting urination, pain or bleeding with urination. As they progress, the symptoms can impact on daily life, to the extent that they reduce the quality of life, and interfere with sexual function. Strictly speaking, BPH is diagnosed through histopathological investigation, however in the literature it is often described in terms of LUTS, and sometimes the terms are used interchangeably.Measurement of LUTS/BPH symptomsBPH can cause LUTS either by directly obstructing the bladder outlet, or by the increased smooth muscle tone and resistance within the gland. The severity of LUTS is assessed through clinical investigation and documentation of medical history. Measurement of the degree of severity of LUTS can be performed using the International Prostate Symptom Score (IPSS). The IPSS Q8 is a written tool consisting of 8 questions: 7 physical symptom questions (score range 0 to 35) and 1 Quality of Life (QoL) question (6 levels of response ranging from “delighted” to “terrible”) used to screen, diagnose and manage the symptoms of BPH. Threshold scores for mild, moderate and severe disease are used in clinical practice ( REF _Ref503798855 \h Table 2), but there is some disagreement of the usefulness of the scores PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EJmFwb3M7U2lsdmE8L0F1dGhvcj48WWVhcj4yMDE0PC9Z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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EJmFwb3M7U2lsdmE8L0F1dGhvcj48WWVhcj4yMDE0PC9Z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ADDIN EN.CITE.DATA (D'Silva, Dahm & Wong 2014). Scores used to determine the level of severity do not incorporate the Quality of Life score. It is important to use the IPSS score in conjunction with other clinical assessment measures. Another commonly used score is the American Urology Association Symptom Index (AUA-SI), which uses a similar scoring scale to IPSS. Table SEQ Table \* ARABIC 2IPSS score thresholds for LUTS BPH severity levelLevel of severityScore levelMild≤ 7Moderate8 - 19Severe20 - 35BPH = benign prostate hyperplasia; IPSS = International Prostate Symptom score; LUTS = lower urinary tract symptomsPrevalence of BPH and LUTSA combined lifetime prevalence estimate of BPH of 26.2% (95% CI: 22.8 – 29.6%) was published by Lee et al ADDIN EN.CITE <EndNote><Cite><Author>Lee</Author><Year>2017</Year><RecNum>22</RecNum><IDText>7984</IDText><DisplayText>(Lee, Chan & Lai 2017)</DisplayText><record><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516079820">22</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lee, S. W. H.</author><author>Chan, E. M. C.</author><author>Lai, Y. K.</author></authors></contributors><auth-address>School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500, Malaysia. shaun.lee@monash.edu.
School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500, Malaysia.
School of Pharmacy, UCSI Universit, Taman Connaught, 56000, Malaysia.</auth-address><titles><title>The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis</title><secondary-title>Sci Rep</secondary-title></titles><periodical><full-title>Sci Rep</full-title></periodical><pages>7984</pages><volume>7</volume><number>1</number><dates><year>2017</year><pub-dates><date>Aug 11</date></pub-dates></dates><isbn>2045-2322 (Electronic)
2045-2322 (Linking)</isbn><accession-num>28801563</accession-num><urls><related-urls><url>;(Lee, Chan & Lai 2017), pooled from 25 studies using objective measures. According to Lee et al prevalence increased with age, but there was no difference found between rural, urban or mixed sites; countries; respondent representativeness; sample size; or study quality. The prevalence of diagnosed BPH estimated from the Bettering the Evaluation and Care of Health (BEACH) program in Australia was 21.2% (95%CI 17.3, 25.1) overall, with estimates varying by age ( REF _Ref504987567 \h Figure 1) ADDIN EN.CITE <EndNote><Cite><Author>BEACH</Author><Year>2012</Year><RecNum>20</RecNum><DisplayText>(BEACH 2012)</DisplayText><record><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515992182">20</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>BEACH</author></authors><secondary-authors><author>Fasmily Medicine Research Centre, University of Sydney</author></secondary-authors></contributors><titles><title>SAND abstract number 190: Benign prostatic hyperplasia (BPH) and symptoms among male general practice patients aged 40 years or older</title></titles><dates><year>2012</year></dates><urls></urls></record></Cite></EndNote>(BEACH 2012). The BEACH data were based on 707 male patients aged 40 years or older, of whom 150 had been diagnosed with BPH. Of the 243 symptomatic respondents in the BEACH data cohort, 44.9% (109 patients) were being treated for LUTS, and 41% of those being treated (45 patients) were taking medications ADDIN EN.CITE <EndNote><Cite><Author>BEACH</Author><Year>2012</Year><RecNum>20</RecNum><DisplayText>(BEACH 2012)</DisplayText><record><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515992182">20</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>BEACH</author></authors><secondary-authors><author>Fasmily Medicine Research Centre, University of Sydney</author></secondary-authors></contributors><titles><title>SAND abstract number 190: Benign prostatic hyperplasia (BPH) and symptoms among male general practice patients aged 40 years or older</title></titles><dates><year>2012</year></dates><urls></urls></record></Cite></EndNote>(BEACH 2012).Figure SEQ Figure \* ARABIC 1Prevalence of BPH by ageSource: BEACH 2012. Benign prostatic hyperplasia (BPH) among male general practice patients aged 40 years or older. SAND abstract 190 from the BEACH program: FRMC University of Sydney, 2012BEACH = Bettering the Evaluation and Care of Health; BPH = benign prostate hyperplasia; FRMC = Family Medicine Research Centre, University of Sydney; IPSS = International Prostate Symptom score; LUTS = lower urinary tract symptoms; SAND = Supplementary Analysis of Nominated DataEpidemiological data reported that LUTS resulting from BPH affects an estimated 70% of men aged between 61 and 70 years, and 90% of those aged 81 to 90 years ADDIN EN.CITE <EndNote><Cite><Author>Nickel</Author><Year>2006</Year><RecNum>19</RecNum><IDText>5-10</IDText><DisplayText>(Nickel 2006)</DisplayText><record><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515989454">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Nickel, J. C.</author></authors></contributors><auth-address>Department of Urology, Queen's University, Kingston, Ontario, Canada. jcn@post.queensu.ca</auth-address><titles><title>The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis</title><secondary-title>Curr Opin Urol</secondary-title></titles><periodical><full-title>Curr Opin Urol</full-title></periodical><pages>5-10</pages><volume>16</volume><number>1</number><edition>2005/12/31</edition><keywords><keyword>Adrenergic alpha-Antagonists/therapeutic use</keyword><keyword>Chronic Disease</keyword><keyword>Diagnosis, Differential</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Phytotherapy</keyword><keyword>Prostatic Hyperplasia/ complications/diagnosis/epidemiology/therapy</keyword><keyword>Prostatitis/ complications/diagnosis/epidemiology/therapy</keyword></keywords><dates><year>2006</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>0963-0643 (Print)
0963-0643 (Linking)</isbn><accession-num>16385194</accession-num><urls><related-urls><url>;(Nickel 2006). LUTS prevalence was also found to increase with age in estimates pooled across 25 studies by Lee et al. LUTS was defined as moderate or severe symptoms (IPSS or AUA-SI >7) in Lee et al’s study, but authors commented on the presence of heterogeneity amongst the studies in methodology and definitions. Data can be seen in REF _Ref504571793 \h Table 3.Table SEQ Table \* ARABIC 3Prevalence of men with moderate to severe symptoms of LUTS/BPH by age group ADDIN EN.CITE <EndNote><Cite><Author>Lee</Author><Year>2017</Year><RecNum>22</RecNum><IDText>7984</IDText><DisplayText>(Lee, Chan & Lai 2017)</DisplayText><record><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516079820">22</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lee, S. W. H.</author><author>Chan, E. M. C.</author><author>Lai, Y. K.</author></authors></contributors><auth-address>School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500, Malaysia. shaun.lee@monash.edu.
School of Pharmacy, Monash University Malaysia, Bandar Sunway, 47500, Malaysia.
School of Pharmacy, UCSI Universit, Taman Connaught, 56000, Malaysia.</auth-address><titles><title>The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis</title><secondary-title>Sci Rep</secondary-title></titles><periodical><full-title>Sci Rep</full-title></periodical><pages>7984</pages><volume>7</volume><number>1</number><dates><year>2017</year><pub-dates><date>Aug 11</date></pub-dates></dates><isbn>2045-2322 (Electronic)
2045-2322 (Linking)</isbn><accession-num>28801563</accession-num><urls><related-urls><url>;(Lee, Chan & Lai 2017)Age rangePrevalence of LUTS (IPSS or AUA-SI >7)40-49 years14.8%50-59 years20.2%60-69 years29.1%70-79 years36.8%≥ 80 years38.4%AUA-SI = American Urological Association Symptom Index; BPH = benign prostate hyperplasia; IPSS = International Prostate Symptom score; LUTS = lower urinary tract symptomsInterventionVisual laser ablation of the prostate (VLAP; also called photoselective vaporisation of the prostate, PVP) can be performed using a number of laser systems which have the capability of being focused and selectively coagulating or vaporising prostate tissue. The laser systems use a side-firing technique and can be used with an endoscope through the urethra. Ablation of the prostate by VLAP is practised in Australia on enlarged prostates of any size.VLAP is not a treatment for prostate cancer, and if a malignancy is suspected, a biopsy of the prostate is conducted as a separate procedure to VLAP.VLAP using Greenlight? laser systemsOne photoselective vaporisation system used for VLAP is the Greenlight? laser. The 180W XPS GL (XPS-180) has been developed following earlier trials with green light laser systems with lower power output, and it claims to have a number of advantages over the previous systems ADDIN EN.CITE <EndNote><Cite><Author>Brunken</Author><Year>2015</Year><RecNum>4</RecNum><IDText>531-7</IDText><DisplayText>(Brunken, Seitz & Woo 2015)</DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515631680">4</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Brunken, C.</author><author>Seitz, C.</author><author>Woo, H. H.</author></authors></contributors><auth-address>Department of Urology, Asklepios Klinik St. Georg, Hamburg, Germany.
Department of Urology, Medical University of Vienna, Vienna, Austria.
Sydney Adventist Hospital Clinical School University of Sydney, Wharoonga, NSW, Australia.</auth-address><titles><title>A systematic review of experience of 180-W XPS GreenLight laser vaporisation of the prostate in 1640 men</title><secondary-title>BJU Int</secondary-title></titles><periodical><full-title>BJU Int</full-title></periodical><pages>531-7</pages><volume>116</volume><number>4</number><edition>2014/10/14</edition><keywords><keyword>Aged</keyword><keyword>Humans</keyword><keyword>Laser Therapy/adverse effects/instrumentation/methods</keyword><keyword>Lasers</keyword><keyword>Lower Urinary Tract Symptoms/etiology/surgery</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Prostate/ surgery</keyword><keyword>Prostatic Hyperplasia/complications/surgery</keyword><keyword>180w</keyword><keyword>532 nm</keyword><keyword>Bph</keyword><keyword>GreenLight</keyword><keyword>Luts</keyword><keyword>Xps</keyword><keyword>laser</keyword><keyword>review</keyword><keyword>vaporisation</keyword></keywords><dates><year>2015</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>1464-410X (Electronic)
1464-4096 (Linking)</isbn><accession-num>25307850</accession-num><urls></urls><electronic-resource-num>10.1111/bju.12955</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>(Brunken, Seitz & Woo 2015). The XPS-180 system is the most commonly used for VLAP in Australia. As with other laser systems, the XPS-180 utilises laser energy to vaporise tissue on which it is focused, and thereby remove the tissue. This method does not leave tissue to be removed via the bladder and urethra. VLAP is a transurethral procedure in which access to the prostate is achieved enabling passing of a cystoscope and the laser fibre through the urethra.Green light system wavelengths (532nm) are selectively absorbed by oxyhaemoglobin, making them particularly well absorbed by the vascularised tissue of the prostate. Where vascularisation is low, the laser becomes less efficient, and may lead to longer vaporisation time PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CcnVua2VuPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CcnVua2VuPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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ADDIN EN.CITE.DATA (Brunken, Seitz & Woo 2015; Ding et al. 2012). The XPS-180 system has a relatively shallow depth of action (1 to 2 mm), and because of its coagulative action, it results in minimal bleeding. Patients with comorbidities, or taking anticoagulants may be treated by VLAP using the XPS, and patients can experience relatively short catheterisation time and hospitals stays.The XPS-180 system uses a lithium triborate laser to achieve the 532nm wavelength. Other greenlight options for VLAP exist, and are possibly used in Australian clinics. 120W potassium titanyl phosphate (KTP) laser (Greenlight? HPS-120 Laser Therapy) is an earlier version producing 532nm, as is the first generation Greenlight? 80W system. The higher wattage systems provide a reduced laser footprint and better vaporisation efficiency. Reimbursement of VLAP servicesThe medical service VLAP is currently funded by Medicare Item 37207, with a fee of $866.45 for a single service ( REF _Ref504561517 \h Table 10). The Applicant proposes that because the reimbursement for VLAP is lower than for transurethral resection of the prostate (TURP), it creates a financial incentive for practitioners to choose TURP, despite evidence that VLAP is non-inferior. The purpose of this application is to request an increased fee for VLAP, thereby removing the financial incentive to choose TURP. A second MBS item exists (Item 37208, fee $416.05) for reimbursement of VLAP procedures that are not completed. It would be expected that reimbursement for this item would also increase should this application be successful.RationaleThe laser system is not specified in the Medicare Item descriptor for VLAP, other than that it is to be a side-firing device. Side-firing laser systems designed for the treatment of BPH, that have been trialled successfully on prostate tissue and met TGA requirements should be suitable for claiming the Medicare rebate. VLAP using other laser systemsA number of other systems could be used for VLAP, however they rarely in use in Australia and are not included in this assessment. NOTEREF _Ref508006794 \h \* MERGEFORMAT 2 The diode laser and thulium laser systems can be used for VLAP. For the former technique, a high powered laser beam capable of surgical application (980nm), is emitted by a glass or crystal rod which has been excited using AC power. Diode laser systems are used infrequently in Australia but may be reimbursed under MBS item 37207 for VLAP. The Thulium laser system is not side-firing and is not included in this parator(s)TURP is the most frequently used procedure for reduction of prostate tissue, is used in the same patient population as VLAP and is considered the gold standard for prostate tissue removal ADDIN EN.CITE <EndNote><Cite><Author>2015</Author><Year>2017</Year><RecNum>16</RecNum><IDText>473-480</IDText><DisplayText>(2015 2017; AUA 2010)</DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515636158">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Singapore Urological Association Guidelines Committee 2015</author></authors></contributors><titles><title>Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia</title><secondary-title>Singapore Medical Journal</secondary-title></titles><periodical><full-title>Singapore Medical Journal</full-title></periodical><pages>473-480</pages><volume>58</volume><number>8</number><dates><year>2017</year></dates><pub-location>Singapore</pub-location><publisher>Singapore Medical Association</publisher><isbn>0037-5675</isbn><accession-num>PMC5563527</accession-num><urls><related-urls><url> app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516235353">25</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>AUA</author></authors><secondary-authors><author>McVary KT, Chair, Roehrborn CG, Co-Chair, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster Jr HE, Gonzalez CM, Kaplan SA, Penson, DR, Ulchaker JC, Wei JT </author></secondary-authors></contributors><titles><title>American Urological Guideline: Management of Benign Prostatic Hyperplasia (BPH)</title><secondary-title>AUA guidelines</secondary-title></titles><dates><year>2010</year></dates><urls></urls></record></Cite></EndNote>(2015 2017; AUA 2010). TURP will therefore be the main comparator for VLAP in the assessment. Patients who are eligible for TURP would be considered eligible for VLAP, however the procedure of choice is likely to be limited by the availability of equipment and practitioner training. It is expected that VLAP would further replace TURP in clinical practice if this application were to be successful.TURPTURP is considered the gold standard procedure by many authors for BPH patients when a reduction of prostate tissue is necessary ADDIN EN.CITE <EndNote><Cite><Author>Teo</Author><Year>2017</Year><RecNum>6</RecNum><IDText>195-198</IDText><DisplayText>(Teo, Lee & Ho 2017)</DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515634145">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Teo, Jonathan Shunming</author><author>Lee, Yee Mun</author><author>Ho, Henry Sun Sien</author></authors></contributors><titles><title>An update on transurethral surgery for benign prostatic obstruction</title><secondary-title>Asian Journal of Urology</secondary-title></titles><periodical><full-title>Asian Journal of Urology</full-title></periodical><pages>195-198</pages><volume>4</volume><number>3</number><dates><year>2017</year><pub-dates><date>06/15
03/19/received
05/08/revised
05/08/accepted</date></pub-dates></dates><publisher>Second Military Medical University</publisher><isbn>2214-3882
2214-3890</isbn><accession-num>PMC5717978</accession-num><urls><related-urls><url>;(Teo, Lee & Ho 2017). In Australia, the practise of TURP is not restricted to prostates of any particular size. There are two forms – monopolar (M-TURP) and bipolar (B-TURP). In the monopolar procedure, a high frequency current from a generator is passed through an active electrode, enabling electro-resection via a resectoscope. Lighting and irrigation enable vision for the surgeon while resecting the vascular organ. Pieces of tissue separated from the prostate are flushed into the bladder and then from the body. Bleeding is a common event occurring with incidence of bleeding requiring transfusion of 0.4%-7.1% ADDIN EN.CITE <EndNote><Cite><Author>Teo</Author><Year>2017</Year><RecNum>6</RecNum><IDText>195-198</IDText><DisplayText>(Teo, Lee & Ho 2017)</DisplayText><record><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515634145">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Teo, Jonathan Shunming</author><author>Lee, Yee Mun</author><author>Ho, Henry Sun Sien</author></authors></contributors><titles><title>An update on transurethral surgery for benign prostatic obstruction</title><secondary-title>Asian Journal of Urology</secondary-title></titles><periodical><full-title>Asian Journal of Urology</full-title></periodical><pages>195-198</pages><volume>4</volume><number>3</number><dates><year>2017</year><pub-dates><date>06/15
03/19/received
05/08/revised
05/08/accepted</date></pub-dates></dates><publisher>Second Military Medical University</publisher><isbn>2214-3882
2214-3890</isbn><accession-num>PMC5717978</accession-num><urls><related-urls><url>;(Teo, Lee & Ho 2017).Bipolar TURP, although less frequently practised in Australia, was introduced as an alternative to help reduce side effect of M-TURP. It induces tissue disintegration through molecular dissociation with a high frequency energy. One advantage of the technique is that is can be used with saline irrigation. Placement of active and return electrodes mean high current densities are local and thermal damage to surrounding tissue is reduced. Although trial outcomes have been mixed, it is possible that blood loss is likely to be smaller with B-TURP compared to M-TURP PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5FQVU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxSZWNO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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5FQVU8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxSZWNO
dW0+Mjc8L1JlY051bT48RGlzcGxheVRleHQ+KEVBVSAyMDE2OyBUZW8sIExlZSAmYW1wOyBIbyAy
MDE3KTwvRGlzcGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4yNzwvcmVjLW51bWJlcj48Zm9y
ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImQ1ZGZkc3R2MXJ3c3Y2ZTB3enE1c3Z2b2Y1
ZnR6c3R3ZGR0dCIgdGltZXN0YW1wPSIxNTE2MjM2NzYwIj4yNzwva2V5PjwvZm9yZWlnbi1rZXlz
PjxyZWYtdHlwZSBuYW1lPSJSZXBvcnQiPjI3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo
b3JzPjxhdXRob3I+RUFVPC9hdXRob3I+PC9hdXRob3JzPjxzZWNvbmRhcnktYXV0aG9ycz48YXV0
aG9yPkdyYXZhcyBTIChDaGFpciksIEJhY2ggVCwgRHJha2UgTSwgR2FjY2kgTSwgR3JhdHprZSBD
LCBIZXJybWFubiBUUlcsIE1hZGVyc2JhY2hlciBTLCBNYW1vdWxha2lzIEMsIFRpa2tpbmVuIEtB
TzwvYXV0aG9yPjxhdXRob3I+R3VpZGVsaW5lcyBBc3NvY2lhdGVzOiBNLiBLYXJhdml0YWtpcywg
Uy4gTWFsZGUsIFYuIFNha2thbGlzICwgUi4gVW1iYWNoPC9hdXRob3I+PC9zZWNvbmRhcnktYXV0
aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5UcmVhdG1lbnQgb2Ygbm9uLW5ldXJv
Z2VuaWMgbWFsZSBMVVRTPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkV1cm9wZWFuIEFzc29jaWF0
aW9uIG9mIFVyb2xvZ3kgR3VpZGVsaW5lczwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxkYXRl
cz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6
Ly91cm93ZWIub3JnL2d1aWRlbGluZS90cmVhdG1lbnQtb2Ytbm9uLW5ldXJvZ2VuaWMtbWFsZS1s
dXRzLzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1
dGhvcj5UZW88L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxSZWNOdW0+NjwvUmVjTnVtPjxJRFRl
eHQ+MTk1LTE5ODwvSURUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+NjwvcmVjLW51bWJlcj48Zm9y
ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImQ1ZGZkc3R2MXJ3c3Y2ZTB3enE1c3Z2b2Y1
ZnR6c3R3ZGR0dCIgdGltZXN0YW1wPSIxNTE1NjM0MTQ1Ij42PC9rZXk+PC9mb3JlaWduLWtleXM+
PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRv
cnM+PGF1dGhvcnM+PGF1dGhvcj5UZW8sIEpvbmF0aGFuIFNodW5taW5nPC9hdXRob3I+PGF1dGhv
cj5MZWUsIFllZSBNdW48L2F1dGhvcj48YXV0aG9yPkhvLCBIZW5yeSBTdW4gU2llbjwvYXV0aG9y
PjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5BbiB1cGRhdGUgb24gdHJh
bnN1cmV0aHJhbCBzdXJnZXJ5IGZvciBiZW5pZ24gcHJvc3RhdGljIG9ic3RydWN0aW9uPC90aXRs
ZT48c2Vjb25kYXJ5LXRpdGxlPkFzaWFuIEpvdXJuYWwgb2YgVXJvbG9neTwvc2Vjb25kYXJ5LXRp
dGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFzaWFuIEpvdXJuYWwgb2YgVXJv
bG9neTwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjE5NS0xOTg8L3BhZ2VzPjx2b2x1
bWU+NDwvdm9sdW1lPjxudW1iZXI+MzwvbnVtYmVyPjxkYXRlcz48eWVhcj4yMDE3PC95ZWFyPjxw
dWItZGF0ZXM+PGRhdGU+MDYvMTUmI3hEOzAzLzE5L3JlY2VpdmVkJiN4RDswNS8wOC9yZXZpc2Vk
JiN4RDswNS8wOC9hY2NlcHRlZDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxwdWJsaXNoZXI+
U2Vjb25kIE1pbGl0YXJ5IE1lZGljYWwgVW5pdmVyc2l0eTwvcHVibGlzaGVyPjxpc2JuPjIyMTQt
Mzg4MiYjeEQ7MjIxNC0zODkwPC9pc2JuPjxhY2Nlc3Npb24tbnVtPlBNQzU3MTc5Nzg8L2FjY2Vz
c2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmlo
Lmdvdi9wbWMvYXJ0aWNsZXMvUE1DNTcxNzk3OC88L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+
PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai5hanVyLjIwMTcuMDYuMDA2PC9lbGVj
dHJvbmljLXJlc291cmNlLW51bT48cmVtb3RlLWRhdGFiYXNlLW5hbWU+UE1DPC9yZW1vdGUtZGF0
YWJhc2UtbmFtZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=
ADDIN EN.CITE.DATA (EAU 2016; Teo, Lee & Ho 2017).TURP syndrome is a serious complication which can occur with TURP. It is thought to be caused by the use of irrigation fluids of lower osmolality than serum during the procedure. Perforation of capsular veins and sinuses may occur as a result. TURP syndrome is characterised by mental confusion, nausea, vomiting, hypertension and bradycardia, and can lead to cerebral oedema and sometimes death. Preventative measures should be taken to avoid this side effect.TURP can provide a sample of prostatic tissue for histology analysis, which occasionally identifies tumour cells. The Medicare item descriptor identified for reimbursement of TURP is shown in REF _Ref504032516 \h Table 4.Table SEQ Table \* ARABIC 4MBS item descriptor for TURP Category 3 – THERAPEUTIC PROCEDURES37203PROSTATECTOMY (endoscopic, using diathermy or cold punch), with or without cystoscopy and with or without urethroscopy, and including services to which item 36854, 37201, 37202, 37207, 37208, 37245, 37303, 37321 or 37324 appliesMultiple Services Rule(Anaes.)Fee: $1,042.15 Benefit: 75% = $781.65TURP = transurethral resection of the prostateRationaleThere are a number of other procedures used for prostate surgery, although the eligible patients for each procedure may vary. The procedures discussed here are either funded by Medicare or in common use in Australia in some populations of patients with BPH. Alternative comparatorsFor very large prostates, alternative methods using laparoscopic, robotic or open surgical techniques are more likely to be used. Some patients with very large prostates (> 80-100ml), or other comorbidities may be recommended for open surgery rather than TURP or VLAP. Open prostatectomy is not a comparator for VLAP in this assessment.There are several other procedures used for the treatment of LUTS/BPH. They are generally known as TUNA (transurethral radio-frequency needle ablation, Item 37201), TUMT (transurethral microwave thermotherapy, Item 37230), TUIP (transurethral incision of the prostate) and HoLEP (Holmium: YAG laser enucleation of the prostate, Item 37245). TUIP, TUMT and TUNA are not considered best practice in Australia and are rarely used procedures. They are not suitable comparators for VLAP. HoLEP may be considered a minor comparator. HoLEPHoLEP employs laser technology for tissue resection. A specific wavelength created by using holmium: YAG (crystals of yttrium, aluminium and garnet, doped with holmium) can be focussed for accurate cutting of prostate tissue. As with TURP, resected portions of tissue are flushed into the bladder and then finally from the body. HoLEP was approved for funding in November 2012 for treatment of moderate to severe BPH. HoLEP was not considered an alternative to OP at that time. Usage of HoLEP is low and not expected to change if this application is successful. It is therefore not considered a comparator for VLAP in this assessment. The number of requests for HoLEP from July 2011 to June 2017 can be seen in REF _Ref505249918 \h Table 5.Current use of VLAP and comparatorsUsage of relevant Medicare items from July 2011 to June 2017 is reported in REF _Ref505249918 \h Table 5.Table SEQ Table \* ARABIC 5Requested Medicare items processed from July 2011 to June 2017 ItemJul 2011 - Jun 2012Jul 2012 - Jun 2013Jul 2013 - Jun 2014Jul 2014 - Jun 2015Jul 2015 - Jun 2016Jul 2016 - Jun 2017Total37203TURP12,18311,25210,78810,89911,14211,285 (76.6%)67,539 (79.4%)37207VLAP1,4372,1392,7422,9372,8112,612 (17.7%)14,678 (17.3%)37245HoLEPNA81548641733837 (5.7%)2,840 (3.3%)Total13,62013,47214,07814,47714,68614,73485,057Source: Statistical report from Medicare statistics onlineHoLEP = holmium: YAG laser enucleation of the prostate; OP = open prostatectomy; TUMT = transurethral microwave thermotherapy of the prostate; TUNA = transurethral needle ablation; VLAP = visual laser ablation of the prostateBy far the most commonly used procedure is TURP (79.4% of claims), followed by VLAP (17.3% of claims). Together these two procedures, shown by the highlighted rows in Table 4, make up 97% of all procedures claimed. Of note is the gradual increase in the total number of procedures over time, a trend which is expected to continue into the future. An estimate of the projected number of all procedures to the year 2022 has been provided by the applicant ( REF _Ref508267120 \h Figure 2). Using the projected estimate of 16,000 services in total for 2022, the expected number of TURP services would be 12,160 and PVP services would be 2,816 in that year, based on the proportion of each service claimed in 2016-2017. Figure SEQ Figure \* ARABIC 2Projected market size for MBS items 37203 (TURP), 37207 (PVP), and 37245 (HoLEP)Source: MSAC Application 1518, Application form, Boston ScientificOutcomesPatient-relevant outcomesSafety outcomes related to the procedure, associated anaesthetic and hospital stay should be considered. Clinical effectiveness should be measured by the change in LUTS, preferably using standardised scoring systems such as IPSS. Other similar scores, such as the American Urology Association Symptom Index (AUA-SI), may also be found in the literature. Other standard measures for achieving reduction of prostate volume and function should also be included. Treatment failure rate varies between procedures and is another important outcome to be considered, along with re-treatment rate. Quality of life is strongly linked to LUTS in BPH patients and should also be assessed. Length of hospital stay may be an important outcome to assess safety. PASC also requested that the impact of tumour detection (through histology of the specimen retrieved by TURP) be considered (i.e. in those where a malignancy is not suspected, and where a separate biopsy would not be requested, concurrent with VLAP). Safety outcomes relevant to this assessment are:Immediate complicationsBleedingAcute urinary retentionInfectionTURP syndrome (dilutional hyponatraemia)MortalityLonger term complicationsUrethral strictureErectile dysfunctionUrinary incontinenceLength of hospital stayClinical effectiveness outcomes relevant to this assessment are:Symptom severity related to LUTS – IPSS, AUA-SI Peak flow (Qmax)Post-void residual volumeProstate volumeQuality of lifeTreatment failure rateRe-treatment rateProstate cancer detection rate and clinical implicationsThe GOLIATH studyThe GOLIATH study compared XPS-180 and TURP in prospective randomised controlled trial conducted in 29 centres across Europe. The IPSS was used to evaluate the non-inferiority of the XPS-180, along with secondary outcomes of Qmax, prostate volume and other standardised measures. A total of 269 patients who were complication free and with inclusion criteria of IPSS ≥ 12, and prostate size ≤ 100g underwent either treatment. Over a 2 year follow-up period, XPS-180 was found to have similar efficacy and safety to TURP for treatment of prostate enlargement PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYWNobWFubjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYWNobWFubjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+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ADDIN EN.CITE.DATA (Bachmann et al. 2014, 2015; Thomas et al. 2016). Healthcare systemShould the reimbursement for VLAP increase, it is expected that there would be an increase in its use and an equivalent decease in the use of TURP. There would be an additional cost to Medicare as all VLAP and TURP procedures would be charged at the current reimbursement rate for TURP, provided the two methods have similar safety and effectiveness. In addition there may be an increased gap fee that will need to be covered by the patient.Should VLAP be found to be safer or more effective than TURP, requiring fewer re-treatments, or reduced symptom treatment there may be some cost recovery. Should VLAP be found to be less safe and effective than TURP, then there may costs to the Department on top of the additional cost of reimbursement fees.It is expected that VLAP would require shorter hospital stays than TURP ADDIN EN.CITE <EndNote><Cite><Author>Ow</Author><Year>2018</Year><RecNum>31</RecNum><IDText>95-99</IDText><DisplayText>(Ow et al. 2018)</DisplayText><record><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1525668961">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ow, D.</author><author>Papa, N.</author><author>Perera, M.</author><author>Liodakis, P.</author><author>Sengupta, S.</author><author>Clarke, S.</author><author>Bolton, D. M.</author><author>Lawrentschuk, N.</author></authors></contributors><auth-address>Department of Surgery, The University of Melbourne, Melbourne, Victoria, Australia.
Olivia Newton-John for Cancer Research Institute, Heidelberg Branch, Austin Health, Melbourne, Victoria, Australia.
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</auth-address><titles><title>Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital</title><secondary-title>ANZ J Surg</secondary-title></titles><periodical><full-title>ANZ J Surg</full-title></periodical><pages>95-99</pages><volume>88</volume><number>1-2</number><edition>2017/03/21</edition><keywords><keyword>anticoagulant</keyword><keyword>benign prostatic hyperplasia</keyword><keyword>laser therapy</keyword><keyword>photovaporization</keyword><keyword>risk factor</keyword><keyword>urology</keyword></keywords><dates><year>2018</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1445-2197 (Electronic)
1445-1433 (Linking)</isbn><accession-num>28317227</accession-num><urls></urls><electronic-resource-num>10.1111/ans.13904</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>(Ow et al. 2018), and this may lead to cost savings and improved recovery for patients. However there may be significant cost to private clinicians who want to transfer their services from TURP to VLAP and need to purchase capital equipment to do so (for example if VLAP is performed in day surgery clinics). These additional costs may be borne by private patients.RationaleThe applicant provided an estimate of costs arising if VLAP was approved for a fee increase. The applicant acknowledged that for patients who use VLAP at the current MBS fee, the proposed increase in the fee will be an additional cost to the MBS without any change in health outcomes. However, it is proposed that the overall costs (including hospitalisation costs of the respective procedures) would be greater for TURP than for VLAP, primarily due to reduced hospital time for VLAP. Therefore, the more VLAP procedures substituted for TURP, the greater the savings for the healthcare system as a whole. For example, the 3,378 PVP procedures in year 4 at a fee which might be $200 higher than what is currently reimbursed would cost the MBS an additional $675,600. However, cost data in REF _Ref504651137 \h Table 6 show that each VLAP procedure is associated with hospital cost savings of $3,321 per patient compared to TURP. So the additional 238 VLAP procedures performed because of this better incentivised MBS fee will yield savings of $790,398 to hospitals and net savings of $114,798 to the health care system as a whole. Please note, the applicant provided these figures and calculations for illustrative purpose only and they are likely to change in a submission based assessment (SBA).Table SEQ Table \* ARABIC 6Estimation of PVP services from 2 to 4 years after proposed fee increase ParameterYear 1Year 2Year 3Year 4Estimated market size (number of services)15,20715,42515,64215,860Projected PVP market share – current MBS fee19.9%20.4%20.9%21.3%Estimated services at current MBS fee3,0263,1473,2693,378Projected increase in PVP market share due to proposed fee increase0.0%0.5%1.0%1.5%Estimated additional services due to fee increase077156238Total projected market share – proposed fee19.9%20.9%21.9%22.8%Total estimated PVP services3,0263,2243,4263,616Source: MSAC Application 1518, Application form, Boston ScientificFees charged for prostate resection items 37203 (TURP) and 37207 (VLAP) were sought from MBS statistics. On average, the fees charged do reflect the difference in MBS reimbursement. For 2016-17, the median fee charged for TURP was $1636.20 (IQR $1581.8, $2081.8), and the median charge for VLAP was $1481.4 (IQR $1315.4, $2850.0). The gap between the median fees charged and the amount reimbursed (75% of the MBS item fee) was $831.55 for VLAP and $854.55 for TURP. Current and proposed clinical management algorithm for identified populationThe current management pathway is illustrated in REF _Ref504554524 \h Figure 3.In its early stages, LUTS/BPH can be managed with medical treatment, however when the disease develops, surgical options are used for management. Decision making for surgical options is based on clinical assessment of the impact of LUTS symptoms, the IPSS score, patient age and comorbidities. The general practitioner (GP) is responsible for diagnosis and initial management of patients with BPH. Early BPH (IPSS < 4) may be managed with watchful waiting and lifestyle changes, and a number of medical interventions are used for mild to moderate symptoms with IPSS scores of ≥ 4 ADDIN EN.CITE <EndNote><Cite><Author>Spatafora</Author><Year>2012</Year><RecNum>12</RecNum><IDText>279-301</IDText><DisplayText>(Spatafora et al. 2012)</DisplayText><record><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1515635651">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Spatafora, Sebastiano</author><author>Casarico, Antonio</author><author>Fandella, Andrea</author><author>Galetti, Caterina</author><author>Hurle, Rodolfo</author><author>Mazzini, Elisa</author><author>Niro, Ciro</author><author>Perachino, Massimo</author><author>Sanseverino, Roberto</author><author>Pappagallo, Giovanni Luigi</author><author>for the, Auro it B. P. H. Guidelines Committee</author></authors></contributors><titles><title>Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it</title><secondary-title>Therapeutic Advances in Urology</secondary-title></titles><periodical><full-title>Therapeutic Advances in Urology</full-title></periodical><pages>279-301</pages><volume>4</volume><number>6</number><dates><year>2012</year></dates><pub-location>Sage UK: London, England</pub-location><publisher>SAGE Publications</publisher><isbn>1756-2872
1756-2880</isbn><accession-num>PMC3491760</accession-num><urls><related-urls><url>;(Spatafora et al. 2012). Medical therapies vary according to symptoms and patient co-morbidities. The IPSS questionnaire (including the QoL score) is recommended for symptom assessment. When severe or high impact symptoms are diagnosed, referral to a specialist is recommended. This may occur at initial assessment of a patient, or as symptom severity increases despite medical treatment. Progression of BPH from mild to moderate and eventually to severe impact is common as the prostate enlarges over time (illustrated by the dotted lines in REF _Ref504554524 \h Figure 3).The EAU guidelines make recommendations for surgical treatment for men with bothersome LUTS refractory to conservative or medical therapy or in cases of absolute indications for surgery. Surgical management takes into consideration the patient’s prostate size, cardiovascular risk and ability to have anaesthesia ADDIN EN.CITE <EndNote><Cite><Author>EAU</Author><Year>2016</Year><RecNum>27</RecNum><DisplayText>(EAU 2016)</DisplayText><record><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516236760">27</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>EAU</author></authors><secondary-authors><author>Gravas S (Chair), Bach T, Drake M, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Mamoulakis C, Tikkinen KAO</author><author>Guidelines Associates: M. Karavitakis, S. Malde, V. Sakkalis , R. Umbach</author></secondary-authors></contributors><titles><title>Treatment of non-neurogenic male LUTS</title><secondary-title>European Association of Urology Guidelines</secondary-title></titles><dates><year>2016</year></dates><urls><related-urls><url>;(EAU 2016). Table SEQ Table \* ARABIC 7EAU recommendations for surgically indicated patients with LUTS ADDIN EN.CITE <EndNote><Cite><Author>EAU</Author><Year>2016</Year><RecNum>27</RecNum><DisplayText>(EAU 2016)</DisplayText><record><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516236760">27</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>EAU</author></authors><secondary-authors><author>Gravas S (Chair), Bach T, Drake M, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Mamoulakis C, Tikkinen KAO</author><author>Guidelines Associates: M. Karavitakis, S. Malde, V. Sakkalis , R. Umbach</author></secondary-authors></contributors><titles><title>Treatment of non-neurogenic male LUTS</title><secondary-title>European Association of Urology Guidelines</secondary-title></titles><dates><year>2016</year></dates><urls><related-urls><url>;(EAU 2016)RecommendationsLEaGRaHolmium laser enucleation and 532-nm laser vaporisation of the prostate are alternatives to transurethral resection of the prostate (TURP) in men with moderate-to-severe LUTS leading to immediate, objective, and subjective improvements comparable with TURP.1aAThe short-term and mid-term functional results of 532-nm laser vaporisation of the prostate are comparable with TURP.1bAThe long-term functional results of holmium laser enucleation are comparable with TURP or open prostatectomy.1bAThulium enucleation may be an alternative to TURP and holmium laser enucleation in men with moderate-to-severe LUTS leading to immediate and mid-term objective and subjective improvements.1bADiode laser operations lead to short-term objective and subjective improvement1bBTm:YAG vaporesection is an alternative to TURP for small- and medium-size prostates.1bAWith regard to intra-operative safety and haemostatic properties, diode and thulium lasers appear to be safe.3CWith regard to intra-operative safety, 532-nm laser vaporisation is superior to TURP.1bA532-nm laser vaporisation should be considered in patients receiving anticoagulant medication or with a high cardiovascular risk.3BEAC = European Association of Urology; LUTS = lower urinary tract symptoms; Tm:YAG = thulium doped yttrium, aluminium and garnet laser; TURP = transurethral resection of the prostate a References used were assessed according to their level of evidence (LE) and Guidelines are given a grade of recommendation (GR), according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence.Surgical therapy (including VLAP), is indicated for patients meeting one or more of the listed criteria. After the patient has undergone surgical treatment, he will be followed up either by the urologist/surgeon or referred back to his GP for follow-up. The Andrology Australia Clinical Summary Guide (2014) recommends follow up at 6 weeks, 12 weeks and 6 months in the first year after surgery, and annually thereafter. Symptom assessment using a standardised test (IPSS) should be performed at follow-up to determine the successfulness of the procedure, and whether there is a requirement for retreatment. Choice of VLAP or TURPIn Australia, VLAP may be chosen to treat BPH, depending on access to equipment and training of the practitioner. TURP, on the other hand, is more accessible to most practitioners. VLAP can be performed on patients who are taking anti-coagulants, whereas patients undergoing TURP would be required to stop anti-coagulants prior to treatment. Multiple TURP procedures may be required over time to reduce the prostate, in contrast to VLAP, for which only one application of VLAP is usually needed to achieve the desired outcome. Currently, no Australian guidelines exist. The Urological Society of Australia and New Zealand (USANZ) does not have any published guidelines for LUTS, but endorses the EAU guidelines. The European Association of Urology (EAU, 2016) published guidelines Treatment of Non-neurogenic Male LUTS are used by practitioners in Australia. Andrology Australia guidance is not considered current ADDIN EN.CITE <EndNote><Cite><Author>Australia</Author><Year>2014</Year><RecNum>28</RecNum><DisplayText>(Australia 2014)</DisplayText><record><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516238925">28</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>Andrology Australia</author></authors><secondary-authors><author>Andrology Australia</author></secondary-authors></contributors><titles><title>BPH and Prostatitis - Diagnosis and Mangement</title><secondary-title>Clinical summary guide</secondary-title></titles><dates><year>2014</year></dates><pub-location>Australia</pub-location><publisher>AA</publisher><urls></urls></record></Cite></EndNote>(Australia 2014).Repeat and incomplete proceduresThe need for re-intervention is a significant consideration with regard to BPH surgical treatments. Re-intervention rates published in a recent randomised controlled trial by Bachmann et al PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYWNobWFubjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CYWNobWFubjwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+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ADDIN EN.CITE.DATA (Bachmann et al 2014) were 9.6% for XPS VLAP and 13.5% for TURP. These rates could be broken down into re-interventions following early adverse advents (within 30 days) or late adverse events (30 to 80 days) post surgery. Projecting these rates onto the number of services performed in the 2016-2017 period provides an estimate of re-intervention procedures for that period ( REF _Ref504659014 \h Table 8).Table SEQ Table \* ARABIC 8Procedures and estimated re-interventions for the period July 2016 to June 2017ProcedureNumber of proceduresRe-interventions totalRe-interventions from early adverse events (≤30 days)Re-interventions from late adverse events (30-80 days)TURP11,2851,523 (13.5%)1106 (9.8%)429 (3.8%)VLAP2,612251 (9.6%)76 (2.9%)172 (6.6%)PVP = Photoselective vaporisation of the prostate; TURP = Transurethral resection of the prostateThe surgical procedures TURP and VLAP have other (separate) MBS items for practitioners to bill/claim when the procedures are not completed. In REF _Ref504987899 \h Table 9, the total claims for incomplete procedures are listed for the period July 2011 to June 2017, alongside the total claims for completed procedures. The proportion of all procedures that are incomplete is also given. There is no item for an incomplete HoLEP procedure.Table SEQ Table \* ARABIC 9Comparison of complete and incomplete procedures for BPH for the period July 2011 to June 2017ProcedureMBS itemCompleted procedures (N)MBS itemIncomplete procedures (N)% Incomplete/ totalTURP3720367,539372061690.25VLAP3720714,67837208140.095TUMT = Transurethral microwave thermotherapy of the prostate; TUNA = Transurethral needle ablation; TURP = Transurethral resection of the prostate; VLAP = Visual laser ablation of the prostateNote: NHMRC guidelines for management of LUTS/BPH published in 1994 and 2000 are now rescinded. International guidelines for treatment of LUTS BPH which may be useful are listed. Treatment of non-neurogenic male LUTS, European Association of Urology Guideline, 2016Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia, Singapore Urological Association Guidelines Committee, 2015Lower urinary tract symptoms in men: management (CG97), NICE Guideline, NHS, 2010American Urological Guideline: Management of Benign Prostatic Hyperplasia (BPH), AUA guidelines, 2010Spatafora et al, Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it, Therapeutic Advances in Urology, 2012Figure SEQ Figure \* ARABIC 3Current and proposed clinical management pathway for patients with BPHHoLEP = holmium: YAG laser enucleation of the prostate; OP = open prostatectomy; TURP = transurethral resection of the prostate; VLAP = visual laser ablation of the prostateExpected changes to clinical management algorithm for identified populationClinical management of patients is not expected to change if this application for increased funding is approved for VLAP, because VLAP is already subsidised and utilised across Australia. However, an increased MBS fee for VLAP would expect to result in a shift of patients undergoing TURP to VLAP (usage of TURP and VLAP are indicated by the solid and dashed lines in Figure 3). Currently TURP is the most commonly used service for treatment of severe symptomatic LUTS BPH for prostates between 30 and 80ml in size. It is expected this proportion would reduce, and the proportion of VLAP services would increase. HoLEP is another surgical alternative for treating the population of patients with severe symptoms. However, despite being approved for subsidy in 2012, its usage has remained lower than TURP and VLAP. HoLEP has a higher MBS fee than either TURP or VLAP ($1,262.15). According to the Public Summary Document for HoLEP (MSAC Application 1149 ADDIN EN.CITE <EndNote><Cite><Author>MSAC</Author><Year>2012</Year><RecNum>29</RecNum><DisplayText>(MSAC 2012)</DisplayText><record><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="d5dfdstv1rwsv6e0wzq5svvof5ftzstwddtt" timestamp="1516756774">29</key><key app="ENWeb" db-id="">0</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>MSAC</author></authors><secondary-authors><author>MSAC</author></secondary-authors></contributors><titles><title>1149-PSD-HolmiumYAG laser enucleationof the Prostate</title><secondary-title>MSAC Public Summary Documents</secondary-title></titles><dates><year>2012</year></dates><pub-location>Canberra</pub-location><publisher>Department of Health, Australia</publisher><urls></urls></record></Cite></EndNote>(MSAC 2012)), an MBS fee between $1,000 and $1,262 was considered reasonable and cost-effective by MSAC when compared to TURP (prostate < 80-100gm) or OP (prostate > 80-100gm). It is unlikely the number of claims for HoLEP would change significantly should this application be successful. PASC therefore did not recommend a comparison of VLAP and HoLEP was necessary. Proposed economic evaluationThe applicant’s clinical claim is that VLAP is non-inferior for effectiveness and safety, compared to the main comparator TURP. The economic evaluation recommended is therefore a cost-minimisation analysis (CMA). PASC Comments and requirementsPASC noted the MBS listing of VLAP preceded MSAC, and although a full revisiting/review of safety, efficacy and cost-effectiveness of the procedure is not required, a review of evidence comparing TURP and side-firing laser technology is required. PASC recommended sourcing other studies to reassure MSAC that laser is not inferior to TURP. PASC agreed that, given the claim of non-inferiority and identification of cost offsets, a utilisation and financial comparison is reasonable, but requested the following issues be addressed:Histology following TURP – consider savings if VLAP is performed, but also the cost of missing potential tumours that are normally identified from histology following TURP (The incidence was recently reviewed by {Perera, 2016, 11-4})Consumables- clarify differences between the proceduresOut-of-pocket costs for patients – review available data to advise MSAC whether an increase in MBS fee is likely to result in increased co-payments for patients. This issue needs to be addressed, despite claims from the applicant and clinical expert that private health insurance rebates keep this in check.PASC recommendations for the assessmentPASC determined this application does not need a full submission-based assessment (SBA). Rather, a fit-for-purpose SBA should be lodged by the applicant, for initial consideration by MSAC Executive (and possible subsequent referral to ESC for examination of utilisation and financial impacts of the fee increase). The fit-for-purpose SBA should consider the following:The main high-quality, comparative evidence on efficacy and safety is to stem from the GOLIATH study (GreenLight? Laser Therapy vs. TURP), which appears to be the only RCT on this technology. For this application, it is doubtful that a further literature review on efficacy would be helpful, but sourcing other studies that provide evidence comparing laser and TURP may help to reassure MSAC. The main outcome of reduced length of stay (compared to TURP), assuming equivalent safety and effectiveness, should be examined by obtaining and analysing information of a non-randomised nature. This can be achieved through examining use of VLAP and TURP in Australia. It should be noted that the GOLIATH study was undertaken in Europe, with no Australian sites. Sufficient Australian data should be available on co-claiming (through the MBS) and length of stay (through AIHW hospital separations). This can initially be presented to MSAC Executive in the fit-for-purpose SBA, together with utilisation and financial impact information associated with the proposed fee increase. MSAC Executive will then advise on possible subsequent referral to ESC and/or MSAC.The fit-for-purpose SBA should include analysis of the utilisation and financial impacts of the fee increaseProposed item descriptorPublic funding is sought for an increase to the reimbursement for MBS item 37207. The item descriptor (wording) of the MBS item used for the VLAP service would remain unchanged. It is only the MBS fee that would change (the $ amount from which the patient rebate is calculated) ( REF _Ref504561517 \h Table 10). The applicant claims that non-inferiority and the cost saving nature of VLAP (compared to TURP) support a fee for VLAP at least equivalent to TURP ($1,042.15). If the SBA proposes a higher fee than TURP, a cost-effectiveness (rather than cost-minimisation) approach would be required. The applicant states that a higher fee should minimise financial disincentive, reflect superior resource utilisation outcomes and additional procedure duration of VLAP over TURP. The exact fee to be proposed will be justified in the SBA.The proposed fee in REF _Ref504561517 \h Table 10 is based on the fee for TURP (MBS item 37203). Table SEQ Table \* ARABIC 10Proposed MBS item descriptorCategory 3 – THERAPEUTIC PROCEDURES37207PROSTATE, endoscopic non-contact (side-firing) visual laser ablation, with or without cystoscopy and with or without urethroscopy, and including services to which items 36854, 37201, 37202, 37203, 37206, 37245, 37321 or 37324 applies Multiple services rule(Anaes.)Proposed MBS Fee: $1,042.15 Benefit: 75% (in-hospital only) = $781.65*Current MBS Fee: $866.45 Benefit: 75% (in-hospital only) = $649.85 37208PROSTATE, endoscopic non-contact (side firing) visual laser ablation, with or without cystoscopy and with or without urethroscopy, and including services to which item 36854, 37303, 37321 or 37324 applies, continuation of, within 10 days of the procedure described by items 37201, 37203, 37207 or 37245 which had to be discontinued for medical reasonsMultiple Services Rule(Anaes.)Proposed MBS Fee: To be determined. Current MBS Fee: $416.05 Benefit: 75% (in-hospital only) = $312.05*Note the proposed fee for item 37207 is equivalent to the fee for TURPReferences ADDIN EN.REFLIST 2015, SUAGC 2017, 'Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia', Singapore Medical Journal, vol. 58, no. 8, pp. 473-480.AUA 2010, American Urological Guideline: Management of Benign Prostatic Hyperplasia (BPH), AUA guidelines.Australia, A 2014, BPH and Prostatitis - Diagnosis and Mangement, Clinical summary guide, AA, Australia.Bachmann, A, Tubaro, A, Barber, N, et al 2014, '180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study', Eur Urol, vol. 65, no. 5, May, pp. 931-942.Bachmann, A, Tubaro, A, Barber, N, et al 2015, 'A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study', J Urol, vol. 193, no. 2, Feb, pp. 570-578.Barbalat, Y, Velez, MC, Sayegh, CI & Chung, DE 2016, 'Evidence of the efficacy and safety of the thulium laser in the treatment of men with benign prostatic obstruction', Therapeutic Advances in Urology, vol. 8, no. 3, 02/24, pp. 181-191.BEACH 2012, SAND abstract number 190: Benign prostatic hyperplasia (BPH) and symptoms among male general practice patients aged 40 years or older.Brunken, C, Seitz, C & Woo, HH 2015, 'A systematic review of experience of 180-W XPS GreenLight laser vaporisation of the prostate in 1640 men', BJU Int, vol. 116, no. 4, Oct, pp. 531-537.Cetinkaya, M, Onem, K, Rifaioglu, MM & Yalcin, V 2015, '980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study', Urol J, vol. 12, no. 5, Nov 14, pp. 2355-2361.D'Silva, KA, Dahm, P & Wong, CL 2014, 'Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review', JAMA, vol. 312, no. 5, Aug 6, pp. 535-542.Ding, H, Du, W, Lu, ZP, Zhai, ZX, Wang, HZ & Wang, ZP 2012, 'Photoselective green-light laser vaporisation vs. TURP for BPH: meta-analysis', Asian J Androl, vol. 14, no. 5, Sep, pp. 720-725.EAU 2016, Treatment of non-neurogenic male LUTS, European Association of Urology Guidelines.Lee, SWH, Chan, EMC & Lai, YK 2017, 'The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis', Sci Rep, vol. 7, no. 1, Aug 11, p. 7984.Li, Z, Chen, P, Wang, J, et al 2016, 'The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis', Medicine, vol. 95, no. 24, 06/17MSAC 2012, 1149-PSD-HolmiumYAG laser enucleationof the Prostate, MSAC Public Summary Documents, Department of Health, Australia, Canberra.Nickel, JC 2006, 'The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis', Curr Opin Urol, vol. 16, no. 1, Jan, pp. 5-10.Ow, D, Papa, N, Perera, M, et al 2018, 'Trends in the surgical treatment of benign prostatic hyperplasia in a tertiary hospital', ANZ J Surg, vol. 88, no. 1-2, Jan, pp. 95-99.Pascoe, C, Ow, D, Perera, M, Woo, HH, Jack, G & Lawrentschuk, N 2017, 'Optimising patient outcomes with photoselective vaporization of the prostate (PVP): a review', Transl Androl Urol, vol. 6, no. Suppl 2, Jul, pp. S133-141.Perera, M, Lawrentschuk, N, Perera, N, Bolton, D & Clouston, D 2016, 'Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years', Prostate Int, vol. 4, no. 1, Mar, pp. 11-14.Spatafora, S, Casarico, A, Fandella, A, et al 2012, 'Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it', Therapeutic Advances in Urology, vol. 4, no. 6, pp. 279-301.Teo, JS, Lee, YM & Ho, HSS 2017, 'An update on transurethral surgery for benign prostatic obstruction', Asian Journal of Urology, vol. 4, no. 3, 06/15Thomas, JA, Tubaro, A, Barber, N, et al 2016, 'A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study', Eur Urol, vol. 69, no. 1, Jan, pp. 94-102.Appendix A MBS statistics on fees chargedGiven the hypothesis that the MBS fee listed for a procedure would influence which procedure a physician would recommend, it was thought important to determine what fees were actually charged to patients for TURP (item 37203) and VLAP (item 37207). MBS statistics in REF _Ref508271957 \h Table 11 show the range of fees charged for each procedure, across different percentiles. Table SEQ Table \* ARABIC 11Fees charged for items 37207 (VLAP) and 37203 (TURP) Financial YearMBS ItemNo. of ServicesMean charge $P10P25P50 (Median)P75P90P952012-1337203TURP 11,263 $1,860.4 1,403.1 1,557.6 1,600.0 2,081.8 2,530.0 3,022.5 2013-1437203TURP 10,798 $1,901.1 1,406.8 1,578.7 1,634.4 2,150.5 2,693.0 3,192.0 2014-1537203TURP10,904 $1,903.7 1,425.0 1,581.8 1,644.5 2,081.8 2,750.0 3,192.0 2015-1637203TURP 11,144 $1,897.9 1,434.6 1,581.8 1,636.2 2,025.4 2,725.0 3,214.3 2016-1737203TURP 11,281 $1,924.8 1,434.6 1,581.8 1,636.2 2,081.8 2,824.9 3,337.5 2012-1337207VLAP 2,141 $1,848.2 1,244.5 1,301.0 1,446.3 2,445.0 3,000.0 3,500.0 2013-1437207VLAP 2,741 $1,717.1 1,221.2 1,315.4 1,376.2 1,885.0 2,639.6 3,250.0 2014-1537207VLAP 2,940 $1,733.5 1,238.9 1,315.4 1,444.2 1,945.0 2,705.0 3,200.0 2015-1637207VLAP 2,813 $1,780.9 1,248.3 1,315.4 1,481.4 1,990.0 2,830.0 3,400.0 2016-1737207VLAP 2,613 $1,750.0 1,248.3 1,315.4 1,481.4 1,900.0 2,850.0 3,400.0 Source: Medicare data accessed February 2018 ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- annexure i
- evaluation and medical management
- pharmacotherapy of benign prostatic hyperplasia
- chronic pelvic pain syndrome cpps or chronic nonbacterial
- transurethral destruction prostate tissue radiofrequency
- 1518 ratified pico confirmation
- rajiv gandhi university of health sciences
- auspar attachment 1 product information for cialis
Related searches
- fedex freight confirmation number
- paid in full confirmation letter
- social security claim confirmation number
- holiday inn confirmation number lookup
- holiday inn reservation confirmation number
- holiday inn confirmation number check
- holiday inn confirmation number
- fedex pickup confirmation number tracking
- holiday inn express confirmation number
- emirates booking confirmation check
- icd 10 code for confirmation of pregnancy
- acog confirmation of pregnancy visit